Latest News
-
Friday - May 17, 2019
Bayer is a main sponsor of the IUPAC International Congress of Crop Protection in Belgium:
Industry experts and scientists will discuss strategies for future weed, disease and pest control in agriculture » more
-
Wednesday - May 15, 2019
Not intended for U.S. and UK Media - Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019
New data for larotrectinib show overall response rates of 94% in children and 76% in adults with TRK fusion cancer; clinical benefit demonstrated in patients with primary central nervous system tumors and brain metastases
In children with TRK fusion cancer (n=34), the overall response rate (ORR) was 94% and durable, with median duration of response (DOR) not reached / In adults with TRK fusion cancer (n=74), the ORR was 76% and durable, with median DOR not reached / In evaluable patients with brain metastases (n=5), ORR was 60% / Improvements in quality of life were shown with larotrectinib treatment in both children and adults / Majority of adverse events were grade 1 or 2, as reported in prior publications » more
-
Monday - May 13, 2019
Bayer statement on jury’s decision in California State Glyphosate Trial » more
-
Monday - May 13, 2019
Beiersdorf to acquire iconic Coppertone™ brand from Bayer
Significant expansion of portfolio will advance Beiersdorf’s leading position as sun care expert / Beiersdorf delivers first major acquisition under its new C.A.R.E.+ strategy / Divestiture enables Bayer to focus on core OTC business » more
-
Monday - May 13, 2019
Not intended for U.S. and UK Media - 2019 American Society of Clinical Oncology (ASCO) Annual Meeting:
Bayer to present new data at ASCO 2019 highlighting commitment to evolve cancer treatment paradigm
Data from Bayer’s growing oncology portfolio include new analyses on the company’s precision oncology treatment larotrectinib, with two oral presentations in patients with solid tumors that harbor an NTRK gene fusion: one on expanded data in pediatric patients and the other one in patients with brain metastases or primary central nervous system tumors / First detailed presentation of quality of life data from the Phase III ARAMIS trial of the investigational androgen receptor antagonist darolutamide in patients with non-metastatic castration-resistant prostate cancer / Oral presentation on investigational ATR inhibitor BAY 1895344 in patients with advanced solid tumors / Long-term data from patients with relapsed or refractory follicular lymphoma treated with copanlisib » more
-
Sunday - May 12, 2019
Bayer commissions external law firm to investigate Monsanto's stakeholder mapping project and reaffirms its commitment to transparency and fair dealings with all stakeholders » more
-
Monday - April 29, 2019
Not intended for U.S. and UK Media
U.S. FDA accepts new drug application and grants priority review for darolutamide » more
-
Monday - April 29, 2019
Not intended for U.S. and UK Media
Study reaffirms safety and efficacy profile of Xarelto™ for the prevention of stroke in patients with atrial fibrillation
First results from RELOADED, an observational study in the EU, indicate that non-vitamin-K oral anticoagulants (NOACs) like Xarelto provide a benefit in renal preservation over time when compared to the vitamin-K antagonist (VKA) phenprocoumon / The data from the comparative effectiveness study in Germany confirm an improved safety outcome and comparable effectiveness for Xarelto compared with phenprocoumon in patients with non-valvular atrial fibrillation (NVAF), including those with renal insufficiency(1) » more
-
Saturday - April 27, 2019
After Annual Stockholders’ Meeting votes to not ratify Board of Management’s actions:
Bayer’s Supervisory Board unanimously stands behind Board of Management » more
-
Friday - April 26, 2019
CEO Werner Baumann at the Annual Stockholders’ Meeting of Bayer AG:
“We made great progress – both operationally and strategically”
Bayer now the leader in agriculture / Lawsuits and first verdicts concerning glyphosate weigh on company / Sales and earnings increased in 2018 / Proposed dividend of 2.80 euros marks record payout by Bayer / Successful start to fiscal 2019 – outlook confirmed » more
-
Thursday - April 25, 2019
First quarter of 2019:
Bayer: strong operational start to the year
Group sales increase 4.1 percent (Fx & portfolio adj.) to 13.015 billion euros / EBITDA before special items advances by 44.6 percent to 4.188 billion euros / Crop Science posts substantial sales and earnings gains following the acquisition / Pharmaceuticals shows encouraging sales and earnings growth / Consumer Health below the prior-year quarter, full-year outlook confirmed / Net income declines as expected by 36.5 percent to 1.241 billion euros, held back by special items related to the acquisition and restructuring / Core earnings per share increase 13.8 percent to 2.55 euros / Business outlook for 2019 confirmed » more
-
Wednesday - April 17, 2019
Partnership for the development of therapeutic antibodies
Bayer Animal Health and adivo sign global collaboration agreement
Bayer to strengthen its portfolio of products for companion animals » more
-
Tuesday - April 16, 2019
Bayer and Fair Planet renew commitment to improve access to seeds in Ethiopia
Five-year renewal aims to improve food and nutrition security, provide economic opportunities for smallholder farmers in Ethiopia » more
-
Friday - April 12, 2019
Dr. Monika Lessl to lead both the Bayer Science and the Bayer Cares Foundations » more
-
Monday - April 8, 2019
Bayer welcomes science-based discussion with regulators, researchers and the public:
More than 100 Bayer-owned glyphosate safety study reports accessible as Monsanto integration continues » more
-
Tuesday - April 2, 2019
Leaps by Bayer and Khloris join forces to develop induced pluripotent stem cells (iPSCs) as breakthrough anti-cancer vaccines
Seed investment of Leaps by Bayer paves an exclusive leadership position for next generation oncology business / Research study from Stanford University suggests that vaccination with iPSCs may cure and prevent the development of many types of cancer » more
-
Tuesday - April 2, 2019
Thought leaders emphasize cattle health and well-being for the sustainable development of the beef industry
More than 220 cattle professionals engage over key topics of parasite control, bovine respiratory disease, reproduction, digital innovation and well-being at the 2nd Bayer International Beef Symposium » more
-
Friday - March 29, 2019
CVBD World Forum discuss a changing world in vector-borne Diseases
The 14th CVBD™ (Companion Vector-Borne Diseases) World Forum welcomed parasitologists, veterinary clinicians and epidemiology experts from around the world to discuss changing parasite and vector distributions in a changing world. / Latest data about spread and prevalence of VBDs from endemic to non-endemic regions & need for vets to be equipped with this data » more
-
Wednesday - March 27, 2019
Bayer statement on jury’s decision in phase two of California glyphosate trial » more
-
Wednesday - March 27, 2019
Not intended for U.S. and UK Media - American Association for Cancer Research (AACR) 110th Annual Meeting:
Bayer to showcase latest oncology research at AACR 2019 underscoring its commitment to advancing the future of cancer care
Data presentation from ongoing Phase I study with BAY 2731954 (formerly LOXO-195), an oral and selective investigational next-generation TRK inhibitor, in patients who have progressed on or were intolerant to prior TRK inhibitors / Bayer committed to expanding its precision oncology portfolio by bringing forward additional projects in this field / Total of 30 presentations on promising projects across key areas of investigation: Oncogenic Signaling, Targeted Alpha Therapies and Immuno-Oncology, underscoring Bayer’s commitment to advancing the future of cancer care » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Download Center - Selection
Bayer TV